Baidu
map

中国科学家发现肝癌发病新机制

2018-04-19 周舟 新华社

18日发表在美国《科学·转化医学》杂志上的一篇论文揭示了非酒精性脂肪肝诱发肝癌的一种发病机制。文章说,已获美国食品和药物管理局批准的一种抗真菌药物或有预防和治疗这类肝癌的功效。

18日发表在美国《科学·转化医学》杂志上的一篇论文揭示了非酒精性脂肪肝诱发肝癌的一种发病机制。文章说,已获美国食品和药物管理局批准的一种抗真菌药物或有预防和治疗这类肝癌的功效。

肝脏脂肪细胞堆积导致的非酒精性脂肪肝是全球最严重的公共健康问题之一,三到四成的成年人受这种疾病危害,并可能发展为肝硬化和肝癌。

中国香港中文大学医学院内科与治疗学系于君教授与刘大斌等研究人员一起,对非酒精性脂肪肝诱发的肝癌肿瘤组织和癌旁肝脏组织的基因组表达进行了分析,发现肝癌发生时肝细胞内“角鲨烯环氧化酶”表达水平显着提高。

于君对新华社记者说,“角鲨烯环氧化酶”是人体内合成胆固醇的关键酶,其过度表达会促进肝细胞胆固醇酯堆积和氧化应激水平升高,后者改变了细胞内甲基化水平,从而促进肝癌发生和发展。

研究人员构建了肝细胞高表达“角鲨烯环氧化酶”的转基因实验小鼠模型,并投喂高胆固醇、高脂肪食品。结果显示,与野生小鼠相比,实验小鼠肝癌发病率显着升高,提示“角鲨烯环氧化酶”可能是非酒精性脂肪肝诱发肝癌的潜在治疗靶标。

实验还发现,一种常用的抗真菌药“特比萘芬”可有效抑制“角鲨烯环氧化酶”的表达,并明显抑制由这种酶介导的肿瘤细胞生长和肝癌发生,显着延长肝癌小鼠的生存期。研究人员认为,这种药的作用机理是降低肝细胞胆固醇酯堆积和氧化应激水平。

于君说,新发现为非酒精性脂肪肝诱发肝癌的预防和治疗提供了新的实验基础和方向。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1799842, encodeId=77301e9984287, content=<a href='/topic/show?id=9e3fe127909' target=_blank style='color:#2F92EE;'>#癌发病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71279, encryptionId=9e3fe127909, topicName=癌发病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2c92500045, createdName=12498636m49(暂无昵称), createdTime=Tue Nov 27 20:47:00 CST 2018, time=2018-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1802540, encodeId=cf11180254056, content=<a href='/topic/show?id=acfae485578' target=_blank style='color:#2F92EE;'>#科学家发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74855, encryptionId=acfae485578, topicName=科学家发现)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e572480, createdName=旅苦化文_208, createdTime=Tue Jun 12 15:47:00 CST 2018, time=2018-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2024325, encodeId=3501202432501, content=<a href='/topic/show?id=79f4219392b' target=_blank style='color:#2F92EE;'>#中国科学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21939, encryptionId=79f4219392b, topicName=中国科学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Sun Jul 08 13:47:00 CST 2018, time=2018-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1516967, encodeId=35b1151696ee0, content=<a href='/topic/show?id=f1232194031' target=_blank style='color:#2F92EE;'>#中国科学家#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21940, encryptionId=f1232194031, topicName=中国科学家)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cbca11021083, createdName=12498e5fm15(暂无昵称), createdTime=Sat Apr 21 08:47:00 CST 2018, time=2018-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=307533, encodeId=198f30e533f6, content=学习学习.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Fri Apr 20 07:35:05 CST 2018, time=2018-04-20, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1799842, encodeId=77301e9984287, content=<a href='/topic/show?id=9e3fe127909' target=_blank style='color:#2F92EE;'>#癌发病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71279, encryptionId=9e3fe127909, topicName=癌发病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2c92500045, createdName=12498636m49(暂无昵称), createdTime=Tue Nov 27 20:47:00 CST 2018, time=2018-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1802540, encodeId=cf11180254056, content=<a href='/topic/show?id=acfae485578' target=_blank style='color:#2F92EE;'>#科学家发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74855, encryptionId=acfae485578, topicName=科学家发现)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e572480, createdName=旅苦化文_208, createdTime=Tue Jun 12 15:47:00 CST 2018, time=2018-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2024325, encodeId=3501202432501, content=<a href='/topic/show?id=79f4219392b' target=_blank style='color:#2F92EE;'>#中国科学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21939, encryptionId=79f4219392b, topicName=中国科学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Sun Jul 08 13:47:00 CST 2018, time=2018-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1516967, encodeId=35b1151696ee0, content=<a href='/topic/show?id=f1232194031' target=_blank style='color:#2F92EE;'>#中国科学家#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21940, encryptionId=f1232194031, topicName=中国科学家)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cbca11021083, createdName=12498e5fm15(暂无昵称), createdTime=Sat Apr 21 08:47:00 CST 2018, time=2018-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=307533, encodeId=198f30e533f6, content=学习学习.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Fri Apr 20 07:35:05 CST 2018, time=2018-04-20, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1799842, encodeId=77301e9984287, content=<a href='/topic/show?id=9e3fe127909' target=_blank style='color:#2F92EE;'>#癌发病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71279, encryptionId=9e3fe127909, topicName=癌发病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2c92500045, createdName=12498636m49(暂无昵称), createdTime=Tue Nov 27 20:47:00 CST 2018, time=2018-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1802540, encodeId=cf11180254056, content=<a href='/topic/show?id=acfae485578' target=_blank style='color:#2F92EE;'>#科学家发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74855, encryptionId=acfae485578, topicName=科学家发现)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e572480, createdName=旅苦化文_208, createdTime=Tue Jun 12 15:47:00 CST 2018, time=2018-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2024325, encodeId=3501202432501, content=<a href='/topic/show?id=79f4219392b' target=_blank style='color:#2F92EE;'>#中国科学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21939, encryptionId=79f4219392b, topicName=中国科学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Sun Jul 08 13:47:00 CST 2018, time=2018-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1516967, encodeId=35b1151696ee0, content=<a href='/topic/show?id=f1232194031' target=_blank style='color:#2F92EE;'>#中国科学家#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21940, encryptionId=f1232194031, topicName=中国科学家)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cbca11021083, createdName=12498e5fm15(暂无昵称), createdTime=Sat Apr 21 08:47:00 CST 2018, time=2018-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=307533, encodeId=198f30e533f6, content=学习学习.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Fri Apr 20 07:35:05 CST 2018, time=2018-04-20, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1799842, encodeId=77301e9984287, content=<a href='/topic/show?id=9e3fe127909' target=_blank style='color:#2F92EE;'>#癌发病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71279, encryptionId=9e3fe127909, topicName=癌发病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2c92500045, createdName=12498636m49(暂无昵称), createdTime=Tue Nov 27 20:47:00 CST 2018, time=2018-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1802540, encodeId=cf11180254056, content=<a href='/topic/show?id=acfae485578' target=_blank style='color:#2F92EE;'>#科学家发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74855, encryptionId=acfae485578, topicName=科学家发现)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e572480, createdName=旅苦化文_208, createdTime=Tue Jun 12 15:47:00 CST 2018, time=2018-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2024325, encodeId=3501202432501, content=<a href='/topic/show?id=79f4219392b' target=_blank style='color:#2F92EE;'>#中国科学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21939, encryptionId=79f4219392b, topicName=中国科学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Sun Jul 08 13:47:00 CST 2018, time=2018-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1516967, encodeId=35b1151696ee0, content=<a href='/topic/show?id=f1232194031' target=_blank style='color:#2F92EE;'>#中国科学家#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21940, encryptionId=f1232194031, topicName=中国科学家)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cbca11021083, createdName=12498e5fm15(暂无昵称), createdTime=Sat Apr 21 08:47:00 CST 2018, time=2018-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=307533, encodeId=198f30e533f6, content=学习学习.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Fri Apr 20 07:35:05 CST 2018, time=2018-04-20, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1799842, encodeId=77301e9984287, content=<a href='/topic/show?id=9e3fe127909' target=_blank style='color:#2F92EE;'>#癌发病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71279, encryptionId=9e3fe127909, topicName=癌发病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2c92500045, createdName=12498636m49(暂无昵称), createdTime=Tue Nov 27 20:47:00 CST 2018, time=2018-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1802540, encodeId=cf11180254056, content=<a href='/topic/show?id=acfae485578' target=_blank style='color:#2F92EE;'>#科学家发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74855, encryptionId=acfae485578, topicName=科学家发现)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e572480, createdName=旅苦化文_208, createdTime=Tue Jun 12 15:47:00 CST 2018, time=2018-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2024325, encodeId=3501202432501, content=<a href='/topic/show?id=79f4219392b' target=_blank style='color:#2F92EE;'>#中国科学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21939, encryptionId=79f4219392b, topicName=中国科学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Sun Jul 08 13:47:00 CST 2018, time=2018-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1516967, encodeId=35b1151696ee0, content=<a href='/topic/show?id=f1232194031' target=_blank style='color:#2F92EE;'>#中国科学家#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21940, encryptionId=f1232194031, topicName=中国科学家)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cbca11021083, createdName=12498e5fm15(暂无昵称), createdTime=Sat Apr 21 08:47:00 CST 2018, time=2018-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=307533, encodeId=198f30e533f6, content=学习学习.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Fri Apr 20 07:35:05 CST 2018, time=2018-04-20, status=1, ipAttribution=)]
    2018-04-20 kafei

    学习学习.谢谢分享

    0

相关资讯

中国肝癌5年生存率仅12.5%,如何改善治疗?

问:肝癌的发生,究竟与什么相关?答:中国的肝炎病人,可以说80%、90%和肝炎病毒感染相关,在我国主要是乙型肝炎,还有一些和丙肝相关。中国是肝癌大国,全球有50%以上的新发和死亡肝癌患者在中国。然而,中国肝癌5年生存率仅为12.5%,远低于日韩等国。如何给肝癌患者更多的期望?“分析一下原因,日本初诊病人60%是早期病人,我国大概15%是早期,意味着85%是中晚期。”在近日举行的中国肝癌领导力论坛

JAMA Oncology:韩国新研究确定乙肝发展为肝癌的很大风险因素

根据在网上发表的一份研究报告,对于慢性乙型肝炎病毒(HBV)患者,体重指数(BMI)与肝细胞癌(HCC)的风险显著相关,女性比男性更容易患肝癌。

JAMA Oncol:传统治疗方式的“逆袭” :TACE+放疗治疗晚期HCC患者

索拉非尼是目前晚期肝细胞癌(HCC)患者的一线治疗药物。近来有研究报道了其它传统的治疗方式,如肝动脉化疗栓塞(TACE)与放疗(RT)联合运用治疗HCC患者,也具备了一定的有效性和安全性。那么传统方式能否“逆袭”成功,请跟随小编一探究竟。

Radiology:利用18F荧光胆碱PET / CT作为慢性肝病的影像生物标志物

目的 探讨肝癌肝叶切除术的Child-Pugh A,B级的慢性肝病患者在联合术前正电子发射断层扫描(PET)和计算机断层扫描(CT)的氟18(18F)荧光胆碱摄取与慢性肝病组织病理学特征的关系。

J Hepatol:他汀 降低肝癌风险的潜力股?

肝细胞癌(HCC)是世界范围内日益严重的健康问题,造成高死亡率,且预后非常差,凶险猛于虎。他汀进入临床已超过20年的历史,大量临床终点研究一致证实他汀给动脉粥样硬化的治疗带来了革命性的改变。在抗肿瘤药物研发大潮的驱动下,“神药”他汀日益显现出作为新的抗肿瘤药物的潜能。

病例:尾状叶肝癌及手术

该患者为一50岁中年女性,20天前在家中无明显诱因发现食欲减退,无头痛、头晕,无畏寒、发热,无心悸、胸闷,无恶心、呕吐,无腹痛、腹泻,无粘液脓血便及黑便,无尿频、尿急、尿痛等不适,遂就诊我院门诊,行磁共振(上腹部)检查提示:上腹部MRI平扫+增强示:1、肝右叶腔静脉旁占位,考虑原发性肝癌并侵犯腔静脉可能性大;2、肝右叶异常信号,考虑小血管瘤;3、双肾小囊肿。  

Baidu
map
Baidu
map
Baidu
map